
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.

Long COVID, which has affected more than 400 million people around the world, is often underreported, particularly in low- and middle-income countries (LMICs).
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance